Ulcerative Colitis

"The CHMP's positive opinion represents a milestone in the treatment of Spiegel, M.D., chief medical officer and senior vice president of medical affairs, Schering-Plough Research Institute.

"In the pivotal clinical studies, patients receiving REMICADE achieved high rates of clinical response and clinical remission as well as mucosal healing and reduced rates of hospitalization.

These are excellent results for this patient population that had failed available therapeutic options." The CHMP recommendation is an important step towards a European Commission approval.

A Commission approval of the application will result in Marketing Authorization with unified labeling that will be valid in all EU-member states, including the current 25 member states as well as Iceland and Norway.

The positive opinion for REMICADE for UC is based on data from the ACT 1 and ACT 2 clinical trials.

ACT 1 and ACT 2 were multicenter, Phase 3, randomized, double-blind, placebo-controlled, clinical trials conducted to evaluate the ...

30, 2006) * Gained U.S.

approval for a new indication for the once-daily, broad- spectrum antibiotic AVELOX - treatment of complicated intra-abdominal infections (cIAI) in adults.

Available in tablet and intravenous formulations, AVELOX was developed by Bayer Pharmaceuticals Corporation and is marketed in the United States by Schering-Plough.

(Announced Nov.

30, 2005) * Announced that Schering-Plough's Board of Directors unanimously agreed to two corporate governance enhancements.

First, to recommend to shareholders that the company's charter and bylaws be amended to provide for the annual election of directors.

A shareholder vote on this matter will be included on the agenda for the 2006 annual meeting of shareholders.

Second, to revise its corporate governance guidelines to provide that, should a director receive a majority of votes cast at a meeting as "withhold votes," then the director will submit an offer to resign to the Nominating and Corporate Governance Committee, which will determine what action is best for the company in light of the then current facts and circumstances.

The revisions to the corporate governance guidelines will be finalized prior to the 2006 annual meeting of shareholders.

(Announced Dec.

15, 2005) Fourth Quarter 2005 Conference Call and Webcast Schering-Plough will conduct a conference call today at 8 a.m.

(EST) to review the ...

He initiated the campaign No Guts - Know Glory, as he had a strong inclination for sports and other outdoor activities.

ConvaTec, who specializes in the manufacturing of ostomy and wound care products, sponsored this expedition.

It is his fifth quest to scale the tallest peaks on the seven continents.

He wants to send across to the world the message that people like him should not quit living their life.

Crohn’s disease is a chronic inflammatory disease affecting both the small and large intestines (bowel) and is otherwise called as the Inflammatory Bowel Disease (IBD).

Statistics show that nearly 1.5 million Americans suffer from Crohn's disease and And about 750,000 Americans live with an ostomy because of IBD, colorectal cancer or other chronic bowel or bladder diseases.

.newsborders { BORDER-RIGHT: #aeaeae 1px solid; BORDER-TOP: #aeaeae 1px solid; MARGIN: 3px; BORDER-LEFT: #aeaeae 1px solid; BORDER-BOTTOM: #aeaeae 1px solid; } Page 1 2 Next Email Print Save Link Comments Health NewsMon, 30 Jan 2006 The Noro menace: A virus that strikes!

Deer once again in trouble, due to deer disease!

FDA Moves In To Check Listeria Abbott Receives CE Mark Certification Early Detection Of Primary Liver Cancer Would Save Millions Of Lives New Treatment Offers Hope For Lung Cancer Patients ...